TRUST study data confirms safety and efficacy of erlotinib for advanced lung cancer

Featured in the October edition of the Journal of Thoracic Oncology, data from the Tarceva Lung Cancer Survival Treatment, or TRUST, confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor tyrosine-kinase activity in a large heterogeneous non-small cell lung cancer population.